Developed by Kashiv BioSciences with Alvotech, the add-on treatment is also known as ADL-018/AVT23. Amneal acquired Kashiv in August.
Adcomfo received authorization from the United Kingdom Medicines and Healthcare products Regulatory Agency in March. Amneal said its application for the proposed biosimilar to Novartis’ XOLAIR remains under review in the United States.

Comments (0)
No comments yet. Be the first!